A Nationwide Study on Hypertrophic Cardiomyopathy in Iceland: Evidence of a MYBPC3 Founder Mutation.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Maron, Barry J
Burke, Michael A
Gudbjartsson, Daniel F
DePalma, Steven R
Seidman, Jonathan G
Seidman, Christine E
Gunnarsson, Gunnar Th
MetadataShow full item record
Abstract-The geographic isolation and homogeneous population of Iceland is ideally suited to ascertain clinical and genetic characteristics of hypertrophic cardiomyopathy (HCM) at the population level.
-Medical records and cardiac imaging studies obtained between 1997 and 2010 were reviewed to identify Icelandic patients with HCM. Surviving patients were recruited for clinical and genetic studies. A previously identified Icelandic mutation, MYBPC3 c.927-2A>G, was genotyped, and mutation-negative samples were sequenced for HCM genes and other hypertrophic genes. Record review identified 180 HCM patients. Genetic analyses of 151 patients defined pathogenic mutations in 101 (67%), including MYBPC3 c.927-2A>G (88 patients; 58%), 4 other MYBPC3 or MYH7 mutations (5 patients; 3.3%), and 2 GLA mutations (8 patients; 5.3%). Haplotype and genetic genealogical data defined MYBPC3 c.927-2A>G as a founder mutation, introduced into the Icelandic population in the 15(th) century, with a current population prevalence of 0.36%. MYBPC3 c.927-2A>G mutation carriers exhibited phenotypic diversity but were younger at diagnosis (42 vs. 49 years, p=0.001) and sustained more adverse events (15% vs. 2%, p=0.02) than mutation-negative patients. All-cause mortality for HCM patients was similar to an age-matched Icelandic population (Hazard Ratio 0.98, p=0.9). HCM-related mortality (0.78%/year) occurred at a mean age of 68 compared to 81 years for non-HCM related mortality (p=0.02).
-A founder MYBPC3 mutation that arose over 550 years ago is the predominant cause of HCM in Iceland. The MYBPC3 c.927-2A>G mutation is associated with low adverse event rates but earlier cardiovascular mortality, illustrating the impact of genotype on outcomes in HCM.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Circulation
- A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
- Authors: Teirlinck CH, Senni F, Malti RE, Majoor-Krakauer D, Fellmann F, Millat G, André-Fouët X, Pernot F, Stumpf M, Boutarin J, Bouvagnet P
- Issue date: 2012 Nov 10
- A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
- Authors: Calore C, De Bortoli M, Romualdi C, Lorenzon A, Angelini A, Basso C, Thiene G, Iliceto S, Rampazzo A, Melacini P
- Issue date: 2015 May
- Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
- Authors: Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ
- Issue date: 2004 Nov 2
- Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
- Authors: Cardim N, Perrot A, Santos S, Morgado P, Pádua M, Ferreira S, Reis RP, Monteiro C, Ferreira T, Correia JM, Osterziel KJ
- Issue date: 2005 Dec
- Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
- Authors: van Velzen HG, Schinkel AFL, Oldenburg RA, van Slegtenhorst MA, Frohn-Mulder IME, van der Velden J, Michels M
- Issue date: 2017 Aug